Society for Pediatric Dermatology   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Indianapolis IN United States (1975)

Organization Overview

First Clinical Trial
2002
NCT00312520
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (3)

hypochlorous acid (1 trial)

mupirocin (bactroban) (2 trials)

petrolatum, white (Vaseline) (1 trial)

Drugs in Phase 3 Trials (2)

methylprednisolone (medrol) (1 trial)

prednisone (meticorten) (1 trial)

Drugs in Phase 2 Trials (1)

timolol (blocadren) (1 trial)

Drugs in Phase 1 Trials (3)

polyvinylidene difluoride (1 trial)

sirolimus (rapamune) (1 trial)

tacrolimus (prograf) (1 trial)

Drugs in Other Trials (1)

oxybutynin (ditropan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angiofibroma (Phase 1)

Dermatitis (Phase 4)

Dermatitis, Atopic (Phase 4)

Eczema (Phase 4)

Hemangioma (Phase 3)

Hemangioma, Capillary (Phase 2)

Neurofibroma (Phase 1)

Neurofibromatoses (Phase 1)

Neurofibromatosis 1 (Phase 1)

Port-Wine Stain (Phase 2)

Sclerosis (Phase 1)

Staphylococcal Infections (Phase 4)

Tuberous Sclerosis (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 10